Nektar Hit with Class Action Lawsuit Alleging Trial Integrity Issues Amid Critical Phase 3 Preparation

What happened

A shareholder class action lawsuit was filed against Nektar Therapeutics, alleging false and misleading statements about the REZOLVE-AA trial's enrollment and protocol standards. The lawsuit claims these issues could significantly harm the trial's results and overall integrity, directly challenging the company's disclosures and governance. According to the DeepValue report, Nektar is in a precarious position, with a 'WAIT' rating due to heavy reliance on a $300M equity raise and Phase 3 initiation for rezpegaldesleukin in atopic dermatitis by Q2 2026, all while burning cash. This legal action introduces new operational and reputational risks that could undermine investor confidence, complicating the already fragile financing and execution milestones. If substantiated, the allegations may delay or impair clinical progress, exacerbating existing risks around capital needs and trial timelines.

Implication

The lawsuit exposes potential lapses in Nektar's trial management, increasing the likelihood of regulatory scrutiny and potential delays to the REZOLVE-AA trial or related programs. Legal proceedings may drain financial resources and divert management attention during a critical period, impacting the $300M equity raise and Phase 3 start for atopic dermatitis. Investor trust could erode, leading to punitive financing terms or failed capital access, which the DeepValue report identifies as a key downside boundary. Even if separate from the lead asset, trial integrity issues threaten overall company credibility, making it harder to attract partners or maintain market valuation. This amplifies the existing 'WAIT' thesis by adding legal overhangs that could accelerate bear scenarios, urging investors to monitor developments closely before committing capital.

Thesis delta

The DeepValue thesis already highlights financing and Phase 3 execution as primary risks, but this lawsuit introduces a new, material risk of trial integrity failures and potential misrepresentation. This could accelerate downside scenarios by eroding investor confidence, complicating capital raises, and delaying clinical milestones, even if REZOLVE-AA is distinct from the lead program. Investors should now factor in legal uncertainties as an additional layer of risk, reinforcing the 'WAIT' stance until clarity on both the lawsuit and operational catalysts emerges.